BLFS

BioLife has spent the last two years remaking itself from a sprawling cold-chain conglomerate into a focused bioproduction-tools pure-play for the cell & gene therapy (CGT) market. The MD&A documents the cleanup: Global Cooling (2024), SciSafe and CBS (late 2024), and SAVSU (Oct 2025) were all divested and are now discontinued operations, while the company bought in the remaining 90% of PanTHERA in April 2025. That explains the volatile revenue line — $119M (FY21) collapsing to $68M (FY23) — and the FY25 reacceleration to $96.2M (+28.9%) is the first clean read on the slimmed-down core. The quality of that core is genuinely good: 64.6% gross margin on a biopreservation-media razor/razor-blade model, operating cash flow of +$20.1M (up 138.6%), essentially no debt (LT debt $0, $5.0M current), $372M of equity against just $34M of liabilities (0.09x), and a ~6x current ratio. This is not a balance-sheet-stress story.

But the income statement is not there yet, and the headline 'improvement' is partly cosmetic. Net loss narrowed 77% to -$4.59M, yet operating income went the other way — -$16.6M, a -270.8% swing — meaning the bottom-line progress is driven by items below the operating line (divestiture/discontinued-ops effects), not by the core turning profitable. Strong OCF alongside a -17.3% operating margin signals heavy non-cash charges (stock comp) rather than operating earnings. Cash also fell 63.9% to $33M, consumed largely by the PanTHERA deal; OCF positivity keeps this from being a liquidity worry, but the cushion is thinner than the equity figure implies, and the -$340M accumulated deficit underscores that this company has never sustainably earned its cost of capital (ROE -1.2%).